Investigational drug selumetinib reported to confer benefit to patients with KRAS mutated NSCLC in phase 2 trial

What's exciting about Selumetinib?

Selumetinib, a MEK inhibitor developed by AstraZeneca, is an investigational therapy currently in clinical trials for non-small cell lung cancer (NSCLC) and several other cancer types. Recent results from a phase 2 clinical trial (NCT00890825) have demonstrated that selumetinib given in combination with docetaxel has "promising efficacy, albeit with a higher number of adverse events than with docetaxel alone, in previously treated advanced KRAS-mutant NSCLC" (Janne PA, et al. 2013). This is the first prospective study to demonstrate clinical benefit of a targeted therapy for KRAS mutation-positive NSCLC patients.

Selumetinib targets the mitogen-activated protein kinase kinases (MEK or MAPK/ERK kinases) that function downstream of RAS.

What are its side effects?

Side effects associated with selumetinib have been reported as mild, and the toxicity profile is favorable in comparison to other targeted agents and chemotherapies. The most common side effects are rash, fatigue, diarrhea, and peripheral edema. Only 16% of patients discontinued selumetinib therapy due to adverse events.

Selumetinib is available in clinical trials

Selumetinib is not yet approved by the FDA. It is currently in clinical trials for various cancer types including NSCLC, thyroid cancer, melanoma, pancreatic cancer, lymphoma, colorectal cancer and others. Your patient could access this drug by enrolling in a clinical trial.



Name(s) Target Manufacturer Status
Selumetinib MAP2K1, MAP2K2 Array BioPharma Investigational

Clinical Trials